Cadila Healthcare in pink of health on launch of Zolmitriptan in US

The announcement was made after market hours on Thursday, 16 May 2013.

Meanwhile, the BSE Sensex was up 5.21 points or 0.03% at 20,252.54.

On BSE, 891 shares were traded in the counter as against average daily volume of 6,612 shares in the past one quarter.

The stock hit a high of Rs 845 and a low of Rs 835.80 so far during the day. The stock had hit a 52-week high of Rs 964 on 12 September 2012. The stock had hit a 52-week low of Rs 705.05 on 4 June 2012.

The large-cap pharmaceutical company has equity capital of Rs 102.37 crore. Face value per share is Rs 5.

Cadila Healthcare announced the launch of Day 1 launch of Zolmitriptan orally disintegrating tablets upon receiving the final approval from the US FDA. The company is marketing the product in the strengths of 2.5 mg and 5mg in the US market. The drug had annual sales of $175 million in the US in 2012 as per IMS Health data.

Cadila Healthcare said that the company now has 79 approvals and has so far filed 173 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

Cadila Healthcare's consolidated net profit declined 31% at Rs 102.91 crore on 15.4% growth in net sales to Rs 1561.02 crore in Q3 December 2012 over Q3 December 2011.

Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products. The group's operations range from API to formulations, animal health products and cosmeceuticals. Headquartered in the city of Ahmedabad in India, the group has global operations in four continents spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets.

Powered by Capital Market - Live News